CovidVax | show full list |
distribution (started in December 2020): Albania, Algeria, Armenia, Azerbaijan, Bangladesh, Benin, Bosnia and Herzegovina, Botswana, Brazil, Cambodia, Chile, China, Colombia, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Ethiopia, Georgia, Guinea, Hong Kong, Indonesia, Laos, Libya, Malaysia, Mexico, North Macedonia, Northern Cyprus, Oman, Pakistan, Palestine, Paraguay, Philippines, Rwanda, Singapore, Somalia, Sudan, Syria, Tajikistan, Thailand, Timor, Tunisia, Turkey, Uganda, Ukraine, Uruguay, Uzbekistan, Venezuela, Yemen, Zimbabwe |
Feb 08 | Sinovac announced that China's NMPA has granted a conditional marketing authorization for CoronaVac (by sinovacbio.com) |
Feb 03 | Sinovac has officially filed for conditional market authorization for CoronaVac with China's NMPA (by sinovacbio.com) |
Jan 20 | Chile's health regulator approved the emergency roll-out of Sinovac's COVID-19 vaccine (by reuters.com) |
Jan 17 | Anvisa approved Sinovac's COVID-19 vaccine for emergency use in Brazil (by gov.br) |
Jan 13 | Turkey's Medicines and Medical Devices Agency granted emergency use authorization to Sinovac's vaccine (by reuters.com) |
Jan 11 | Indonesia gave Sinovac's vaccine its first emergency use approval outside China launching nationwide inoculations (by reuters.com) |
Aug 11 | Sinovac is hopeful to start producing the vaccine in January 2021 clinical trials are successful (by jakartaglobe.id) |
PHASE 1-2 (Jiangsu)
started April 13 2020 with 744 healthy volunteers aged 18-59 trial location: Xuzhou, Jiangsu, China |
PHASE 1-2 (Hebei)
started May 20 2020 with 422 healthy volunteers aged 60+ trial location: Renqiu, Hebei, China |
PHASE 1-2 (Hebei children)
started September 28 2020 with 552 healthy children aged 3-17 trial location: Shijiazhuang, Hebei, China |
PHASE 3 (Brazil)
started July 2 2020 with 8870 healthy volunteers aged 18+ trial location: Brazil |
PHASE 3 (Indonesia)
started August 10 2020 with 1620 healthy volunteers aged 18-59 trial location: Indonesia |
PHASE 3 (Turkey)
started September 14 2020 with 13000 healthy volunteers aged 18-59 trial location: Turkey |
PHASE 3 (China)
started October 31 2020 with 1040 healthy volunteers aged 18+ trial location: Yancheng, Jiangsu, China |
PHASE 3 (Chile)
started November 27 2020 with 2300 healthy volunteers aged 18+ trial location: Santiago, Chile |
PHASE 4
started February 2021 with 1200 healthy volunteers aged 18+ trial location: Rio De Janeiro, Brazil |
PHASE 4
started February 17 2021 with 30000 healthy volunteers aged 18+ trial location: Sao Paulo, Brazil |
start date: March 2020 |
May 06 | Sinovac's vaccine dosis provided partial or complete protection in macaques (by sciencemag.org) |
Apr 24 | Sinovac published the results of testing their vaccine on animals (by channelnewsasia.com) |
Apr 19 | A Sinovac vaccine candidate successfully gives complete protection in non-human primates (by biorxiv.org) |
currently no early development info |
Dec 06 | Sinovac announced that Sinovac Life Sciences Co.Ltd. has secured US$500M in funding for further devolopment of the vaccine (by businesswire.com) |
May 25 | Advantech Capital and Vivo Capital have invested $7.5m each for Sinovac's vaccine development (by pharmaceutical-technology.com) |